Samsung Ventures
Samsung Ventures, established in 1999, is a corporate venture capital arm of Samsung Electronics, headquartered in Seoul, South Korea. The firm invests globally in emerging technology companies, with a focus on semiconductors, mobile services, internet, software, security, enterprise solutions, bioengineering, and medical sectors. Its investment portfolio spans early-stage startups to pre-IPO companies, with an annual investment budget of $250 million and over $1.8 billion under management. Samsung Ventures operates from key innovation hubs worldwide, including the San Francisco Bay Area, Boston, London, Tel Aviv, Bangalore, Tokyo, and Beijing, to identify and support pioneering startups in areas such as AI, robotics, augmented/virtual reality, and digital health.
Nanoramic Laboratories
Venture Round in 2024
Nanoramic Laboratories is a Boston-based company focused on developing advanced energy storage technologies and materials. It specializes in designing, manufacturing, and licensing Neocarbonix electrodes for rechargeable lithium-ion batteries, as well as producing FastCAP ultracapacitors, which utilize nanocarbon-based electrodes for enhanced performance. The company also offers Thermexit, a line of high-performance thermal interface gap filler pads. Originating from research funded by NASA, the Department of Energy, and the Department of Defense, Nanoramic's innovations aim to revolutionize industries such as electric vehicle batteries and consumer electronics. Established in 2008 and formerly known as FastCAP Systems Corporation, Nanoramic continues to expand its product offerings, which include ultracapacitors capable of operating in extreme temperatures and various energy storage solutions tailored to meet market demands.
BrickBio
Venture Round in 2024
BrickBio, Inc. is a biotechnology company focused on the custom tailoring of proteins through site-specific and site-selective modifications for both research and therapeutic purposes. Founded in 2019 and based in Boston, Massachusetts, BrickBio utilizes a proprietary engineered tRNA synthetase/tRNA pair to enable the selective modification of proteins from eukaryotic and bacterial cell lines. This innovative platform incorporates unnatural amino acids that can be linked to other molecules for various applications, including the development of protein-conjugate therapeutics such as antibody-drug conjugates. By optimizing these modifications, BrickBio aims to enhance the therapeutic efficacy of proteins, facilitating improved treatment options for hospitals and patients.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.